These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 26799187)

  • 1. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis.
    Eke I; Storch K; Krause M; Cordes N
    Cancer Res; 2013 Oct; 73(19):5869-79. PubMed ID: 23950208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
    Serizawa M; Takahashi T; Yamamoto N; Koh Y
    J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells.
    Wang S; Takayama K; Tanaka K; Takeshita M; Nakagaki N; Ijichi K; Li H; Nakanishi Y
    J Thorac Oncol; 2013 Jun; 8(6):719-25. PubMed ID: 23625155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
    Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells.
    Chen JY; Hwang CC; Chen WY; Lee JC; Fu TF; Fang K; Chu YC; Huang YL; Lin JC; Tsai WH; Chang HW; Chen BH; Chiu CC
    Life Sci; 2010 Sep; 87(11-12):350-7. PubMed ID: 20624405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
    Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells.
    Wang Q; Acharya N; Liu Z; Zhou X; Cromie M; Zhu J; Gao W
    J Ethnopharmacol; 2018 May; 217():140-151. PubMed ID: 29458146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
    Lin X; Liao Y; Chen X; Long D; Yu T; Shen F
    Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
    Tsai MS; Weng SH; Chen HJ; Chiu YF; Huang YC; Tseng SC; Kuo YH; Lin YW
    Mol Cancer Ther; 2012 Mar; 11(3):561-71. PubMed ID: 22053010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.
    Xu J; Ni L; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Aging (Albany NY); 2021 Feb; 13(4):5986-6009. PubMed ID: 33612481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.